View Cover Illustration

Targeted Signal Modulation in Renal Cell Carcinoma and Prostate Cancer

Summaries of Lectures From a Satellite Symposium Held in Conjunction With the 2008 Genitourinary Cancers Symposium:
A Multidisciplinary Approach; San Francisco, CA; February 14-16, 2008

1 AMA PRA Category 1 Credit^™

Release date: May 14, 2008
Expiration date: May 14, 2009

Table of Contents

The Success of Targeting the Vascular Endothelial Growth Factor Receptor Axis in Renal Cell Carcinoma

Small-Molecule VEGFR Inhibitors: Integrating Multiple Lines of Therapy for Recurrent Renal Cell Carcinoma

Risk Prognostication and Tumorigenesis in Prostate Cancer

Current Approaches to Prevention and Early Intervention in Prostate Cancer

1. Read the following information before entering the educational activity.
2. Study the educational activity.
3. Complete the CME test.
4. Answer the evaluation questions.
5. After successful completion of the CME test and evaluation, you will receive your certificate of credit online.

• Complete the evaluation and CME test by May 14, 2009, to receive your certificate of credit online.
• CME credit will be granted for only 1 form of participation, either online or via the printed publication.

Improved diagnosis and treatment of renal cell carcinoma (RCC) and prostate cancer have been achieved through the delineation of the molecular pathogenesis of these diseases. Patients with RCC can be treated with 3 US Food and Drug Administration–approved vascular endothelial growth factor (VEGF)–targeted agents, and several agents have entered the approval process for the treatment of advanced disease. With the observation of acquired resistance to VEGF-targeted multikinase inhibitors, the optimal sequencing or combination of these agents is being investigated in the metastatic setting. Increased understanding of the molecular basis for acquired resistance to kinase inhibitors further improves clinical trial design and, thus, patient outcome. Although progress has been made in the characterization of the early molecular events in prostate cancer, heterogeneity of disease has complicated identification of ubiquitous targets for therapy. Preclinical research to elucidate molecular events that denote prognosis and provide potential targets for therapy, including chemoprevention, are ongoing. Results from trials evaluating 5α-reductase inhibitors in the prevention of prostate cancer have suggested that this class of drugs might provide long-term patient benefit.

The purpose of this activity is to provide medical oncologists with the latest information regarding targeted therapeutics in the treatment of RCC and the prevention of prostate cancer.

• Compare available clinical trial results and data from key phase III trials of antiangiogenic agents in the treatment of advanced/metastatic RCC
• Compare current clinical trial data on second-generation kinase inhibitors of the VEGF pathway that are in clinical development
• Assess the phenomenon of acquired resistance and diminished efficacy for sequential lines of VEGF-targeted multikinase inhibitors and investigative treatment approaches for overcoming resistance
• Summarize current research data on molecular elements of risk prognostication and tumorigenesis in prostate cancer
• Evaluate the effectiveness of 5α-reductase inhibitors in the prevention of prostate cancer

Physicians' Education Resource designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

It is the policy of Physicians' Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians' Education Resource requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians' Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

PER Editorial Staff

Erin Grothey, MS (spouse)
Research Funding – sanofi-aventis U.S
Paid Consultant – Amgen, Bristol-Myers Squibb Company, Genentech, Inc., Roche Pharmaceuticals, sanofi-aventis U.S.

Other PER Staff
No relevant relationships to disclose

Satellite Faculty

Eric Jonasch, MD
Research Funding – CTEP, Genentech, Inc., and Pfizer Inc.
Paid Consultant – Genentech, Inc.
Member of Speaker’s Bureau – Bayer Pharmaceuticals Corporation, Onyx Pharmaceuticals, Inc., and Pfizer Inc.

Roberto Pili, MD
Research Funding – Cephalon, Inc. Locus Pharmaceuticals, and Pfizer Inc.
Paid Consultant – Active Biotech, Adnexus Pharmaceuticals, Cerus Corporation, MGI PHARMA, and Syndex Pharmaceuticals

Susan Slovin, MD, PhD
Paid Consultant – Synarc Inc.
Member of Speaker’s Bureau – AstraZeneca, Novartis Pharmaceuticals Corporation, and sanofi-aventis U.S.

William Oh, MD
Research Funding – Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Inc., Roche Pharmaceuticals, and sanofi-aventis U.S.
Paid Consultant – Abbott Laboratories, Abraxis Oncology, Berlex Oncology, Dendreon Corporation, EyeTech Pharmaceuticals, Inc., Genomic Health, Inc., ImClone Systems Incorporated, Novacea, Inc., Roche Pharmaceuticals, and sanofi-aventis U.S.
Member of Speaker’s Bureau – Amgen, AstraZeneca, Eli Lilly and Company, Novartis Pharmaceuticals Corporation,
and sanofi-aventis U.S.

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is located on the article page. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

An educational grant for this activity was provided by GlaxoSmithKline.

This activity is not sanctioned by, nor a part of, the 2008 Genitourinary Cancers Symposium: A Multidisciplinary Approach.

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

• Microsoft Internet Explorer Downloads (Outside Source)
• Mozilla Firefox Product Page (Outside Source)

Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2008 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, Targeted Signal Modulation in Renal Cell Carcinoma and Prostate Cancer
Physicians' Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3456
Fax: (214) 367-3304
E-mail: editor@pergrouplp.com